Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …

Osteosarcoma is the most common primary bone malignancy in adolescents. Its high
propensity to metastasize is the leading cause for treatment failure and poor prognosis …

Osteosarcoma is one of the most common primary tumours of the bone, with a 5‐year
survival rate of less than 20% after the development of metastases. Osteosarcoma is highly …

The survival rate for metastatic osteosarcoma has not improved for several decades, since
the introduction and refinement of chemotherapy as a treatment in addition to surgery. Over …

Osteosarcoma (OSA) is a type of bone cancer that begins in the cells that form bones. OSA
is a rare mesenchymal bone neoplasm derived from mesenchymal stem cells. Genome …

Osteosarcoma (OS) is the most common malignant bone tumor in children. Despite efforts to
develop and implement new therapies, patient outcomes have not measurably improved …

Long non-coding RNA (lncRNA) DANCR (also known as ANCR)—differentiation
antagonizing non-protein coding RNA, was first reported in 2012 to suppress differentiation …

Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that
participates in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR …

Patients diagnosed with osteosarcoma undergo extensive surgical intervention and
chemotherapy resulting in dismal prognosis and compromised quality of life owing to poor …

Despite the development of novel therapeutic approaches and improved clinical
management, survival from metastatic disease remains poor. Indeed, metastasis accounts …